Wag! Group Co(PET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PET Wag! Group Co

Closed 04-22 16:00:00 EDT

0.0938

+0.0006

+0.64%

盘后0.1000

+0.0062+6.61%

19:53 EDT

High0.1017	Low0.0913	Vol278.01K
Open0.0990	D1 Closing0.0932	Amplitude11.16%
Mkt Cap4.76M	Tradable Cap2.07M	Total Shares50.73M
T/O26.61K	T/O Rate1.26%	Tradable Shares22.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"PET","market":"US","secType":"STK","nameCN":"Wag! Group Co","latestPrice":0.0938,"timestamp":1745352000000,"preClose":0.0932,"halted":0,"volume":278009,"hourTrading":{"tag":"盘后","latestPrice":0.1,"preClose":0.0938,"latestTime":"19:53 EDT","volume":14763,"amount":1353.5432,"timestamp":1745366036743},"delay":0,"floatShares":22064454,"shares":50733823,"eps":-0.392853,"marketStatus":"Closed","change":0.0006,"latestTime":"04-22 16:00:00 EDT","open":0.099,"high":0.1017,"low":0.0913,"amount":26608.03844343,"amplitude":0.111588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.392853,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745395200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0932,"preHourTrading":{"tag":"盘前","latestPrice":0.0998,"preClose":0.0922,"latestTime":"09:17 EDT","volume":3956,"amount":385.62908002,"timestamp":1745327831440},"postHourTrading":{"tag":"盘后","latestPrice":0.1,"preClose":0.0938,"latestTime":"19:53 EDT","volume":14763,"amount":1353.5432,"timestamp":1745366036743},"volumeRatio":0.649246},"requestUrl":"/m/hq/s/PET/wiki","defaultTab":"wiki","newsList":[{"id":"2528748056","title":"Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano","url":"https://stock-news.laohu8.com/highlight/detail?id=2528748056","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528748056?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 21:01","pubTimestamp":1744894860,"startTime":"0","endTime":"0","summary":"Clarity has signed a commercial-scale agreement withNusano, Inc.  for supply of copper-64  isotope.The 190,000 square footNusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci  of copper-64 per day at capacity, which translates into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life, far in excess of commercial scale demands across multiple large indications.Clarity's Executive Chairperson, Dr Alan Taylor, commented, \"The signing of this Supply Agreement with Nusano will complement Clarity's existing network of US-based copper-64 suppliers, providing capacity to ensure abundant and seamless supply of the isotope. As Clarity is generating exceptional data in a number of late-stage clinical trials, we now also have a cost-effective, large-scale supply strategy locked in for the commercial roll-out of our Targeted Copper Theranostics  in the largest healthcare market in the world, the US. This Agreement is an important part","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-signs-high-volume-commercial-130100382.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-signs-high-volume-commercial-130100382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PET","CU6.AU","PET.AU","BK7047","BK4192","BK7096"],"gpt_icon":0},{"id":"2524146431","title":"Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2524146431","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524146431?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 19:30","pubTimestamp":1743593400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 02, 2025  -- Biogen Inc.  today announced that the U.S. Food and Drug Administration  has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide  therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.About BIIB080BIIB080 is an investigational antisense oligonucleotide  therapy designed to target microtubule-associated protein tau  mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer’s disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study  in individuals with early Alzheimer’s disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-investigational-tau-targeting-therapy-113000529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4200","BIIB","LU0234570918.USD","BK4139","LU0109394709.USD","BK4192","IE00B5TLWC47.USD","MAPT","BK4532","BK4585","IE00B894F039.SGD","IE00BYQQ9H92.USD","ASO","LU0889565916.HKD","FAST","IE00B19Z9P08.USD","CSF","BK4561","IE00BFXG0V08.USD","BK4104","PET","BK4588","LU0320765992.SGD","BK4533","IE00B19Z9Z06.USD","BK4023","BK4567"],"gpt_icon":0},{"id":"2524818124","title":"Telix Says First Patient Administered Drug Candidate in Trial for Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524818124","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524818124?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 13:19","pubTimestamp":1743571140,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the first patient has been administered its drug candidate TLX300-CDx in the Phase 1 ZOLAR1 trial for advanced metastatic soft tissue sarcoma , according to a Tuesday statement by the company.The trial aims to assess the drug's biodistribution, safety, and optimal dose using positron emission tomography , the statement said.TLX300-CDx targets PDGFRα, a protein often over-expressed in STS, the statement added.The study will inform future therapeutic approaches for treating the disease, the company said.Telix holds the rights to develop and commercialize the radiolabelled drug, the company added.Shares of the company fell 3% on market close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4192","PET.AU","BK7067","TLX.AU","PET","BK7047"],"gpt_icon":0},{"id":"2524126511","title":"Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524126511","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524126511?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 03:30","pubTimestamp":1743535800,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, April 02, 2025  -- Telix Pharmaceuticals Limited  today announces that a first patient has been dosed in the Phase 1 ZOLAR1 trial of TLX300-CDx  in patients with advanced, metastatic soft tissue sarcoma  at the Melbourne Theranostic Innovation Centre  in Melbourne, Australia.The aim of the trial is to evaluate the safety, pharmacokinetics, biodistribution and dosimetry, and establish the optimal dose of TLX300-CDx in patients with advanced STS, prior to therapeutic studies, based on a theranostic approach. As part of the study, it is also expected that the patient dosimetry and target expression characteristics will inform the final selection of therapeutic radionuclide for this candidate, in conjunction with currently active non-clinical radiation biology studies.Telix intends to develop a novel targeted radionuclide therapy, specific for PDGFRα, which could be used to treat patients with STS. Telix holds the exclusive worldwide rights to develop and commercializ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-announces-first-patient-dosed-193000667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","AEIS","PET.AU","ASX.AU","BK4543","IE00B7SZL793.SGD","PET","BK4192","BK4141","BK7039","SEC.AU","BK7047","ASX","XKO.AU","BK4139","TLX.AU","XAO.AU","TLX","IE00B19Z4B17.USD","BK4526","BK4157","XJO.AU","IE0031619046.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2524141730","title":"Gurit Finalizes Sale of Italian PET Recycling Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2524141730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524141730?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 00:03","pubTimestamp":1743523427,"startTime":"0","endTime":"0","summary":"Gurit Holding AG ( ($CH:GURN) ) has provided an announcement. Gurit Holding AG has completed the divestment of its PET recycling site in Carmignano...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gurit-finalizes-sale-of-italian-pet-recycling-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gurit-finalizes-sale-of-italian-pet-recycling-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4192","PET"],"gpt_icon":0},{"id":"2524130734","title":"Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2524130734","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524130734?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 14:00","pubTimestamp":1743487200,"startTime":"0","endTime":"0","summary":"TORONTO, April  01, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3052978/0/en/Quantum-BioPharma-Announces-Joint-Clinical-Study-With-Massachusetts-General-Hospital-Scientists-to-Validate-a-Novel-Positron-Emission-Tomography-PET-Imaging-Technique-to-Monitor-De.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","BK4504","LU0158827781.USD","JYNT","BK4588","IE00BKVL7J92.USD","LU0225283273.USD","BK4534","LU2357305700.SGD","BK4555","LU1989772840.SGD","LU0314104364.USD","PET","BK4192","BK4185","BK4581","LU1363072403.SGD","BK4551","LU2028103732.USD","BK4596","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU0971096721.USD","QNTM","LU0106261372.USD","LU2347655156.SGD","BK4585","LU1720051017.SGD","LU2271345857.HKD","BK4127","LU0795875086.SGD","LU0795875169.SGD","LU0912757837.SGD","LU0098860793.USD","LU2023251221.USD","LU1162221912.USD","LU2133065610.SGD","LU1074936037.SGD","LCID","LU0320765646.SGD","LU2089283258.USD","LU0267386448.USD","LU2111349929.HKD","BK4099","LU1732800096.USD","LU1989772923.USD","LU2089284900.SGD","BK4007","LU0006306889.USD","BK4516"],"gpt_icon":0},{"id":"2523492666","title":"GE HealthCare's Latest Product Launch to Boost Cardiology Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2523492666","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523492666?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 21:45","pubTimestamp":1743428700,"startTime":"0","endTime":"0","summary":"GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado  injection at the ongoing American College of Cardiology  Annual Scientific Session & Expo. It also plans to unveil the latest version of CASE , powered by its CardioSoft technology, at the ACC.GE HealthCare also plans to showcase CardIQ Suite  and its recently launched AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab editions.GEHC aims to highlight its strategy to leverage AI to help increase efficiency and enable seamless integration of data across the cardiology care pathway by showcasing its latest AI-powered innovations.The latest launch is expected to significantly strengthen GE HealthCare’s Cardiology Solutions unit, thus boosting its overall business.GEHC further stated that the FDA approved Flyrcado for patients with known or suspected CAD in 2024. This is expected to deliver higher diagnostic efficacy, unlike SPECT MPI, the predominant procedure used in nuclear cardiology at present.GE He","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ge-healthcares-latest-product-launch-134500646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","LU1914381329.SGD","IE00BFTCPJ56.SGD","LU1894683264.USD","IE0009355771.USD","BK4585","IE0002141913.USD","MDT","SG9999002224.SGD","BK4192","LU1261432733.SGD","LU0868494617.USD","BK4187","BK4588","BK4501","PET","MMSI","BK4566","LU1291159041.SGD","BK4504","GE","LU1064131342.USD","IE000M9KFDE8.USD","LU0566484027.USD","LU1061106388.HKD","LU1559883803.SGD","LU2089283258.USD","LU1721429741.USD","LU0496365809.HKD","SG9999004303.SGD","IE00B4R5TH58.HKD","LU0820561909.HKD","GEHC","LU1989764748.USD","LU2089284900.SGD","CMS","LU1894683348.USD","LU0211326755.USD","LU0157215616.USD","LU2089984988.USD","LU1093756168.USD","LU2023251221.USD","LU1093756325.SGD","LU0320765489.SGD","LU0265550359.USD","LU0122379950.USD","IE00B3T34201.USD","LU0208291251.USD","ABT"],"gpt_icon":0},{"id":"2523917675","title":"Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917675","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917675?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical mu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052163/36461/en/Voyager-Presents-Robust-Preclinical-Data-from-Tau-Targeting-Gene-Therapy-and-Antibody-Programs-at-AD-PD-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4192","BK4023","LU1169589451.USD","LU1169590202.USD","CTA","PET","PD"],"gpt_icon":0},{"id":"2522306104","title":"ACC 2025: GE HealthCare announces the U.S. launch of pivotal innovations that will help transform the cardiology care pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306104","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306104?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 21:00","pubTimestamp":1743080400,"startTime":"0","endTime":"0","summary":"The much-anticipated Flyrcado  injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery disease, is now available in select U.S. markets and has been granted traditional pass-through payment status by the U.S. Centers for Medicare and Medicaid.CHICAGO, March 27, 2025----GE HealthCare  today announced the U.S. launch of Flyrcado  injection at the 2025 American College of Cardiology  Annual Scientific Session & Expo, taking place March 29-31 in Chicago. Additionally, the company will showcase new AI-powered innovations, reflecting its strategy to leverage AI to help increase efficiency and enable seamless integration of data across the cardiology care pathway. GE HealthCare has been investing in AI for years and has topped the FDA list of AI-enabled device authorizations for three years in a row with 85 authorizations.i. Today, GE HealthCare announced the commercial launch of Flyrcado, a first-of-its-kin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acc-2025-ge-healthcare-announces-130000365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","LU1551013342.USD","BK4208","LU2346227817.USD","BK4082","LU0820562030.AUD","BK4206","LU2756315664.SGD","LU1894683264.USD","LU0689626769.HKD","LU0820561909.HKD","LU2264538146.SGD","LU2543165471.USD","GEHC","LU1064131342.USD","LU0943347566.SGD","BK4588","PET","LU0820561818.USD","LU1093756168.USD","LU1988902786.USD","LU0124676726.USD","LU2756315318.SGD","BK4187","BK4585","LU1261432733.SGD","GE","LU0149725797.USD","LU1894683348.USD","LU0157215616.USD","BK4543","LU2500361329.USD","LU0354030511.USD","LU0689472784.USD","CMS","LU2637428348.USD","BK4501","LU1366333091.USD","LU1093756325.SGD","BK4192","LU0354030438.USD","LU1551013425.SGD","LU0640476718.USD","LU0868494617.USD","LU1280957306.USD"],"gpt_icon":0},{"id":"2522372413","title":"Loop Industries to Participate in Gabelli Funds' 11th Annual Waste & Sustainability Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2522372413","media":"ACCESS Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522372413?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"MONTREAL, QC / ACCESS Newswire / March 27, 2025 / Loop Industries, Inc.  , a clean technology company dedicated to acceleratinga circular plastics economy and circular fashion by manufacturing 100% recycled polyethylene terephthalate  plastic and textile-to-textile polyester fiber, today announced that Daniel Solomita, Founder and CEO, and Kevin O'Dowd, Head of Investor Relations, will be participating in Gabelli Funds' 11th Annual Waste & Sustainability Symposium.Event Details:. During the conference, Loop will hold a group presentation and engage in one-on-one meetings with institutional investors and financial analysts.For More Information:Kevin C. O'Dowd, Investor RelationsLoop Industries, Inc.+1 617-755-4602kodowd@loopindustries.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/loop-industries-participate-gabelli-funds-120000283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4192","BK4090","PET","LOOP"],"gpt_icon":0},{"id":"2522780515","title":"Wag! Group Full Year 2024 Earnings: EPS Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2522780515","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522780515?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:49","pubTimestamp":1742993361,"startTime":"0","endTime":"0","summary":"AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NasdaqGM:PET Earnings and Revenue History March 26th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue was in line with analyst estimates. Earnings per share  missed analyst estimates by 11%.The company's shares are down 22% from a week ago.You should learn about the   6 warning signs  we've spotted with Wag!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wag-group-full-2024-earnings-124921444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PET","PETWW"],"gpt_icon":0},{"id":"2522752706","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2522752706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522752706?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 02:37","pubTimestamp":1742841460,"startTime":"0","endTime":"0","summary":"23andMe  filed for Chapter 11 bankruptcy protection to help facilitate a potential sale, while Anne Wojcicki resigned as chief executive, less than a month after she attempted to acquire the genetic testing firm.Shares slumped 57%, with intraday trading volume of over 5.5 million against a daily average of about 292,000.TransCode Therapeutics  said Sunday it agreed to sell 10.25 million shares and warrants to buy up to 10.25 million shares at $0.98 per share and warrant to raise some $10 million.Shares sank 38% as intraday trading volume rose to over 15.5 million from a daily average of about 6.36 million.Wag!Group  said Monday its board is advancing a review of \"strategic alternatives to identify opportunities to maximize value for shareholders, including potential investments, strategic partnerships, sale, merger, or other strategic transactions involving the company or its assets.\"Shares slid 22% as intraday trading volume rose to over 1.3 million from a daily average of about 665,0","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4192","ME","PET","MEHCQ","PET.AU","RNAZ","BK4121","BK4196","BK4139","BK7047","BK4539"],"gpt_icon":1},{"id":"2521972438","title":"Wag! Group Co reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2521972438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521972438?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 21:31","pubTimestamp":1742823111,"startTime":"0","endTime":"0","summary":"Group Co reports results for the quarter ended December 31 - Earnings SummaryWag!Group Co PET.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended December 31, identical to the same quarter last year.  The mean expectation of two analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -8 cents to -2 cents per share.Revenue fell 28.8% to $15.43 million from a year ago; analysts expected $18.90 million. Wag!Group Co's reported EPS for the quarter was a loss of 10 cents.The company reported a quarterly loss of $4.81 million.Wag!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL5N3Q713V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET"],"gpt_icon":0},{"id":"2521174698","title":"Wag! Group 2025 Outlook: Expects Revenues Of $84M-$88M Vs. $75.30M Est., Sees Adjusted EBITDA Of $2M-$4M","url":"https://stock-news.laohu8.com/highlight/detail?id=2521174698","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521174698?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:04","pubTimestamp":1742814276,"startTime":"0","endTime":"0","summary":"GuidanceFor the full year 2025, we expect:Revenues in the range of $84 million to $88 million.Adjusted EBITDA1 in the range of $2.0 million to $4.0 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44454636/wag-group-2025-outlook-expects-revenues-of-84m-88m-vs-75-30m-est-sees-adjusted-ebitda-of-2m-4m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET"],"gpt_icon":0},{"id":"2521745081","title":"Wag Group Q4 2024 GAAP EPS $(0.10) Misses $(0.05) Estimate, Sales $15.43M Miss $18.90M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745081","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745081?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:01","pubTimestamp":1742814114,"startTime":"0","endTime":"0","summary":"Wag Group (NASDAQ:PET) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.05) by 100 percent. This is a 11.11 percent decrease over losses of $(0.09) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44454598/wag-group-q4-2024-gaap-eps-0-10-misses-0-05-estimate-sales-15-43m-miss-18-90m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET"],"gpt_icon":0},{"id":"2521774682","title":"Wag! Group Co: Q4 Loss per Share $0.10","url":"https://stock-news.laohu8.com/highlight/detail?id=2521774682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521774682?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLX5AB337:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4192","PET"],"gpt_icon":0},{"id":"2521456897","title":"Wag! Group Q4 Revenue USD 15.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2521456897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521456897?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nPLX5AB337:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4192","PET"],"gpt_icon":0},{"id":"2521745693","title":"Wag! Reports Fourth Quarter and Full Year 2024 Results; Announces Review of Strategic Alternatives to Maximize Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745693","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745693?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA2GVWYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4192","PET"],"gpt_icon":0},{"id":"2521745459","title":"Press Release: Wag! Reports Fourth Quarter and Full Year 2024 Results; Announces Review of Strategic Alternatives to Maximize Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745459?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"Reports Fourth Quarter and Full Year 2024 Results; Announces Review of Strategic Alternatives to Maximize Shareholder Value. \"; Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, today announced financial results for the fourth quarter and full year ended December 31, 2024. The Company also announced that its Board of Directors  is advancing its review of strategic alternatives to identify opportunities to maximize value for shareholders, including potential investments, strategic partnerships, sale, merger, or other strategic transactions involving the Company or its assets.\"Our Board and management team continues to believe in the strength of our business, the effectiveness of our strategic plan, and our ability to execute on our strategy to drive value for shareholders,\" said Garrett Smallwood, CEO and Chairman of Wag!. \"We remain focused on strengthening our balance sheet and reducing our deb","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6088","PET","Z4D.SI","BK4192","BK6046"],"gpt_icon":0},{"id":"2521586307","title":"Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2521586307","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521586307?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 10:33","pubTimestamp":1742783582,"startTime":"0","endTime":"0","summary":"The first of two of Opthea’s eye disease trials has failed to meet its primary endpoints. Hitiq has signed a deal with a key Australian Rules amateur league to supply its smart concussion mouthguards. Telix’s FDA news is good for prostate cancer patients in remote areas","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/image-3-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/image-3-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/health-check-optheas-solvency-is-in-question-following-monumental-phase-iii-eye-disease-trial-failure/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4585","BK4217","BK4192","PET","BK4084","BK4134","BK4533","BK4588","PSA","III","OPT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wagwalking.com","stockEarnings":[{"period":"1week","weight":-0.2586},{"period":"1month","weight":-0.6216},{"period":"3month","weight":-0.6509},{"period":"6month","weight":-0.8877},{"period":"1year","weight":-0.9558},{"period":"ytd","weight":-0.6089}],"compareEarnings":[{"period":"1week","weight":-0.0468},{"period":"1month","weight":-0.0888},{"period":"3month","weight":-0.1479},{"period":"6month","weight":-0.1109},{"period":"1year","weight":0.0378},{"period":"ytd","weight":-0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and pet insurance comparison tools. The company was founded in 2014 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.045089},{"month":2,"riseRate":0.75,"avgChangeRate":-0.060703},{"month":3,"riseRate":0.5,"avgChangeRate":-0.095781},{"month":4,"riseRate":0.5,"avgChangeRate":-0.060287},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.095258},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.024941},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.051699},{"month":8,"riseRate":0,"avgChangeRate":-0.329522},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.172971},{"month":10,"riseRate":0.25,"avgChangeRate":0.096569},{"month":11,"riseRate":0.5,"avgChangeRate":-0.221695},{"month":12,"riseRate":0.5,"avgChangeRate":0.064461}],"exchange":"NASDAQ","name":"Wag! Group Co","nameEN":"Wag! Group Co"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Wag! Group Co(PET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Wag! Group Co(PET) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Wag! Group Co,PET,Wag! Group Co股票,Wag! Group Co股票老虎,Wag! Group Co股票老虎国际,Wag! Group Co行情,Wag! Group Co股票行情,Wag! Group Co股价,Wag! Group Co股市,Wag! Group Co股票价格,Wag! Group Co股票交易,Wag! Group Co股票购买,Wag! Group Co股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Wag! Group Co(PET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Wag! Group Co(PET) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction